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Chemotherapy-Response 
Monitoring of Breast Cancer 
Patients Using Quantitative 
Ultrasound-Based Intra-Tumour 
Heterogeneities
Ali Sadeghi-Naini 1,2,3,4, Lakshmanan Sannachi1,2,3, Hadi Tadayyon1,2, William T. Tran3,5, 
Elzbieta Slodkowska6, Maureen Trudeau7, Sonal Gandhi7, Kathleen Pritchard7, Michael C. 
Kolios  8 & Gregory J. Czarnota1,2,3,4
Anti-cancer therapies including chemotherapy aim to induce tumour cell death. Cell death introduces 
alterations in cell morphology and tissue micro-structures that cause measurable changes in tissue 
echogenicity. This study investigated the effectiveness of quantitative ultrasound (QUS) parametric 
imaging to characterize intra-tumour heterogeneity and monitor the pathological response of breast 
cancer to chemotherapy in a large cohort of patients (n = 100). Results demonstrated that QUS 
imaging can non-invasively monitor pathological response and outcome of breast cancer patients to 
chemotherapy early following treatment initiation. Specifically, QUS biomarkers quantifying spatial 
heterogeneities in size, concentration and spacing of acoustic scatterers could predict treatment 
responses of patients with cross-validated accuracies of 82 ± 0.7%, 86 ± 0.7% and 85 ± 0.9% and areas 
under the receiver operating characteristic (ROC) curve of 0.75 ± 0.1, 0.80 ± 0.1 and 0.89 ± 0.1 at 1, 4 
and 8 weeks after the start of treatment, respectively. The patients classified as responders and non-
responders using QUS biomarkers demonstrated significantly different survivals, in good agreement 
with clinical and pathological endpoints. The results form a basis for using early predictive information 
on survival-linked patient response to facilitate adapting standard anti-cancer treatments on an 
individual patient basis.
Breast cancer is the most common malignancy among women in developed countries1. Up to 20% of 
newly-diagnosed breast cancer patients each year present with locally advanced breast cancer (LABC)2–4. LABC 
includes stage III and a subset of stage IIB disease and often presents as tumours greater than 5 cm in size that may 
involve the skin and/or chest wall or be classified as inflammatory breast cancer. Women with locally-advanced 
breast cancer have poor long term survival rates compared to early stage breast cancer patients5. The standard 
treatment for these patients includes neoadjuvant chemotherapy to reduce the size of the tumour, followed by 
surgery and, if required, radiation and/or hormonal therapy6–8. Current methods for monitoring response to 
neoadjuvant chemotherapy rely on gross changes in tumor size based on physical examination or conventional 
anatomical imaging including X-ray mammography and T1/T2-wighted magnetic resonance imaging (MRI). 
A major limitation associated with these methods is that changes in tumor size frequently require up to months 
of therapy and in some cases a mass diminishment is not present despite a positive pathological response to 
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neoadjuvant chemotherapy9. Neither are used routinely to monitor response to neoadjuvant chemotherapy in a 
clinical setting. The standard approach to determine tumour pathological response to neoadjuvant chemotherapy 
is based on post-surgical histopathology. Systematic techniques such as the Miller and Payne (MP) score are used 
to describe pathological response to chemotherapy based on the cellular and histopathological characteristics of 
tumour. The MP score quantifies changes in tumour cellularity in response to therapy based on pre-treatment 
core biopsy and post-treatment surgical specimens10. Pathological response of tumour to neoadjuvant chemo-
therapy has been demonstrated to be highly correlated with improved overall survival7, 11–15. However, previous 
studies on post-surgical evaluation of LABC response to neoadjuvant chemotherapy reported that over 40% of 
patients may demonstrate poor pathological response to treatment16. This highlights the importance of early 
predictions of patient response to chemotherapy, since this can facilitate an opportunity to modify ineffective 
treatments to more effective ones on an individual patient basis, before it is potentially too late17–20.
Functional imaging techniques that can detect changes in tumour micro-structure and physiology in response 
to treatment could provide early assessments of therapy response21–24. In this context, a number of functional 
imaging modalities, including positron emission tomography (PET) and MRI, have recently been demon-
strated capable of evaluating cancer treatment response within weeks after treatment initiation25–28. However, 
these modalities are often costly with long scan times and require administration of exogenous contrast agents 
to detect response-related changes in tumour. Such factors potentially limit the availability and applicability of 
these modalities for treatment response monitoring as well as the number of times that a patient can be scanned 
during a course of treatment. On the other hand, ultrasound is a relatively inexpensive and rapid imaging modal-
ity that relies on the micro-structural and physical properties of tissue to generate contrast and, therefore, does 
not require any exogenous contrast agents to measure changes in cells and tissue microstructure in response to 
treatment29–31.
Quantitative ultrasound (QUS) techniques have previously been used in several tissue characterization 
applications. In particular, QUS parameters derived based on the spectral analysis of phase-resolved ultrasound 
radio-frequency (RF) signal have been applied in the diagnosis of ocular and prostate cancers, the examina-
tion of liver and renal tissues, studies of cardiac and vascular abnormalities, and the characterization of breast 
masses32–35. Measures of ultrasound signal attenuation have also been used to classify different tissue types and 
to detect diseases and abnormalities. Particularly, the attenuation coefficient estimate (ACE) parameter has been 
used to differentiate benign lesions from normal breast tissue, and to classify different tissue types in the breast 
such as fat, parenchyma and invasive ductal carcinoma36, 37. In addition, measures of acoustic scatterer spacing 
have been used to characterize tissues with detectable periodicity in their structural organization. Specifically, the 
spacing among scatterers (SAS) parameter has been applied to characterize diffuse disease of the liver38–40, to dif-
ferentiate normal and pathological breast tissues, and to classify breast tumours in terms of histological grade41, 42. 
In a number of preclinical studies, QUS spectral analysis techniques at low (3–9 MHz) and high (15–50 MHz) 
frequencies have been demonstrated to be effective in detecting tumour response to a variety of anti-cancer ther-
apies including chemotherapy, photodynamic therapy, radiation therapy and ultrasound-stimulated microbubble 
therapy43–50. In recent pilot clinical studies, QUS techniques have been applied to evaluate breast cancer response 
to neoadjuvant chemotherapy within weeks after the start of treatment and demonstrated good correlations with 
clinical response identified at the end of treatment51, 52. In those studies, changes in the QUS parameters, includ-
ing the mid-band fit (MBF), slope, intercept, average scatter diameter (ASD), and average acoustic concentration 
(AAC), were related to alterations in cell ensembles and tissue microstructure in response to treatment. Most 
recently, in addition to QUS mean-value parameters, textural features extracted from QUS parametric maps have 
been investigated for tumour response monitoring in animal tumour models and small patient populations53, 54. 
These textural parameters, which quantify the spatial relationship between local acoustic properties within tis-
sue microstructures, have been demonstrated to be capable of characterizing intra-tumour response heteroge-
neities55. Combined mean-value and textural parameters of the QUS parametric maps improved accuracies for 
detecting tumour response to treatment in a small pilot study54.
The aim of this study was to develop and evaluate multi-parametric QUS models to predict pathological 
response of LABC tumours after the start of neoadjuvant chemotherapy. The sample size here was expanded to a 
large cohort of 100 LABC patients and QUS parameters such as MBF, slope, intercept, ACE, SAS, ASD, and AAC, 
as well as their corresponding textural features such as contrast, correlation, homogeneity, and energy were inves-
tigated using volumetric ultrasound scans of patients. Multi-parametric QUS models for response evaluation 
was developed using k-nearest neighbours (KNN) classifiers in conjunction with a sequential forward feature 
selection method and a leave-one-patient-out scheme for cross-validation.
Material and Methods
Study Protocol. This study was conducted in accordance with institutional research ethics approval from 
Sunnybrook Health Sciences Centre, Toronto, ON, Canada. The study was open to all women with LABC aged 
18–85 who were planned for neoadjuvant chemotherapy followed by a mastectomy or lumpectomy. Patients who 
failed to attend two or more of the ultrasound scans (described below) were eliminated from the study. In keeping 
with this, 100 eligible patients were recruited for the study after obtaining written informed consent and com-
pleted their participation in the study. All patients underwent a core needle biopsy to confirm cancer diagnosis 
(based on radiology reports), and to determine histological subtype, cellularity and hormone receptor status of 
the tumour. Pre-treatment magnetic resonance (MR) images of the breast were acquired for each patient to deter-
mine initial tumour size. Ultrasound scans were performed immediately before the start of chemotherapy (after 
pre-treatment MRI) and at weeks 1, 4, and 8 after the start of treatment. The scans were performed by three expe-
rienced sonographers following a standardized protocol for data acquisition (described below). All scans for each 
patient were typically done by the same sonographer. Ultrasound data was acquired with patients lying supine 
with their arms above their heads. The sonographers were blinded to patient tumour-response characteristics and 
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study results. Patients were also followed clinically up to 5 years after their treatment and their clinical data were 
recorded for recurrence-free survival analysis.
Pathological Response Evaluation. All patients underwent breast surgery after the completion of neoad-
juvant chemotherapy, based on institutional guidelines. The majority of patients (~70%) underwent a mastectomy 
and about 30% of the patients went through a lumpectomy (breast conserving surgery). The average time between 
the first ultrasound scan (baseline) and surgery was about 22 weeks. Following surgery, the surgical specimens 
were prepared on whole-mount 5″ × 7″ pathology slides and stained with hematoxylin and eosin (H&E). The 
slides were digitized using a confocal scanner (TISSUEscopeTM, Huron Technologies, Waterloo, ON). All pathol-
ogy samples were examined by a board-certified pathologist who remained blinded to the study results. Patients 
were classified into two groups based on the identified Miller-Payne scores from pathology reports; responders 
(R): patients with Miller-Payne scores of 3–5 with more than 30% reduction in tumour cellularity in response to 
chemotherapy, and non-responders (NR): patients with Miller-Payne scores of 1 or 2, who demonstrated minimal 
changes in tumour cellularity (less than 30%) after chemotherapy10.
Ultrasound Data Acquisition. Ultrasound data were acquired with a RF-enabled Sonix RP clinical research 
system (Ultrasonix, Vancouver, Canada) equipped with a linear array transducer L14–5/60, operating at a centre 
frequency of ~6 MHz with a −6 dB bandwidth range of 3–8 MHz. The RF data were collected with a 40 MHz sam-
pling frequency and digitized with 16-bit resolution. The sizes of each image frame were 6 cm and 4–6 cm along 
lateral and axial directions, respectively, storing 512 RF lines laterally. For each breast tumour, four to seven image 
planes were typically acquired at approximately 1 cm intervals across the involved breast, with the focal depth set 
at the centre of the tumour. Although the majority of tumours were readily visible with ultrasound, the tumour 
location was also verified using the MR images.
Ultrasound Data Analysis. Analysis of Ultrasound RF data was performed offline using quantitative ultra-
sound spectral analysis to derive mid-band fit (MBF), slope, intercept, spacing among scatterers (SAS), average 
scatterer diameter (ASD), and average acoustic concentration (AAC) parameters41, 48, 51, 56. The attenuation coef-
ficient estimate (ACE) of tumour was calculated using a spectral difference method by estimating the rate of 
change in the spectral power magnitude with depth (over the tumour region) and frequency relative to a reference 
phantom with a known attenuation coefficient57. A reference phantom technique was used to normalize effects of 
the system transfer function, transducer beam-forming, and diffraction artefacts56, 58. The reference phantom was 
composed of 5 to 30 μm diameter glass beads embedded in a homogeneous background of microscopic oil drop-
lets in gelatin (Medical Physics Department, University of Wisconsin, USA). The attenuation coefficient and speed 
of sound parameters of the reference phantom were 0.576 dB/MHz.cm and 1488 m/s, respectively. In estimating 
spectral (MBF, slope, intercept) and backscatter (ASD and AAC) parameters, the ACE of tumour was used for 
attenuation correction of the power spectrum using the point attenuation compensation method59. A two-layer 
(intervening tissue and tumor) attenuation correction was performed using total attenuation estimation57. 
An attenuation coefficient of 1 dB/MHz.cm was assumed for intervening breast tissue based on ultrasound 
tomography measurements of the breast60. Spectral parameters were estimated using linear regression analysis 
on normalized power spectrum over −6 dB bandwidth of the transducer61. The backscatter parameters were 
derived from the backscatter coefficient using a spherical Gaussian form factor model35, 62. The SAS parame-
ter was derived by computing the autocorrelation of the power spectrum estimated by an autoregressive (AR) 
model using Burg’s algorithm40. To estimate the SAS parameter from the peak position, a mean speed of sound of 
1540 m/s was used for the entire breast tissue based on data reported in the literature60.
The spectral, backscatter and SAS parameters were extracted using a sliding window analysis approach (2 
mm × 2 mm windows; 94% adjacent overlap in both axial and lateral directions) to generate parametric images53, 54. 
Ultrasound data were analyzed across all acquired imaging planes through the scan volume that included identifi-
able tumour regions. Analysis parameters were reported from data within a region of interest (ROI) covering the 
entire tumour area within the plane. Parameter values acquired from different imaging planes in each scan were 
reported as tumour volumetric averages.
Texture Analysis. In addition to mean-values of QUS parametric maps, second-order textural features were 
extracted from the parametric images using a grey-level co-occurrence matrix (GLCM) method. The GLCM rep-
resents statistically the angular relationship between neighboring pixels as well as the distance between them55. 
Using the statistics provided by the GLCM for each image, four textural features including contrast, correlation, 
homogeneity, and energy were derived from the MBF, SS, SI, SAS, ASD and AAC parametric maps54. Concisely, 
the contrast parameter represents local gray-level variation of an image, the correlation parameter measures the 
linear dependency among neighbouring pixels, the energy parameter quantifies textural uniformity within neigh-
bouring pixels, and the homogeneity parameter measures the incidence of pixel pairs of different intensities.
Classification and Statistical Analysis. Changes in QUS parameters for each patient during the course 
of treatment were calculated using the corresponding parameters acquired at pre-treatment as the baseline. A 
K-nearest neighbour (KNN) classification was used to evaluate the efficacy of QUS parameters to differentiate 
pathological response of patients at different times after the start of treatment63. Cross-validated sensitivity, spec-
ificity and accuracy were calculated, in addition to the area under the receiver operating characteristic (ROC) 
curve, to measure the performance of the classification. Before performing classification analysis, the patients 
were randomly sub-sampled into 50 subsets with equal numbers of pathological responders and non-responders 
(n = 2 × 19) to compensate for the imbalance in the number of patients in the response populations (81 respond-
ers versus and 19 non-responders)64. The optimal multivariate QUS feature set for each scan time was deter-
mined using a sequential forward feature selection approach. The average cross-validated accuracy of response 
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classification over the 50 subsets was used as the selection criteria. A leave-one-patient-out method was applied 
for cross validation of classification in each subset.
Survival analysis was performed to generate recurrence-free Kaplan-Meier survival curves for the two 
response populations. The patient response was determined at each imaging time during treatment (weeks 1, 4, 
and 8 of chemotherapy) based on the corresponding optimal QUS feature set, and at post-treatment based on his-
topathology. Survival curves were compared using a log-rank test to assess for statistically significant differences 
between the treatment outcomes.
Results
Table 1 summarizes the clinical characteristics of patients and their histopathological response to chemother-
apy. The patients had an average age of 49 years (SD = 11, range: 29–83 years), and an average tumour size of 
5.9 cm (SD = 2.8, range: 2–14 cm) in the longest dimension. Histological tumour types were primarily invasive 
ductal carcinoma (95%) with 5% of cases diagnosed with invasive lobular carcinoma. Also, 63% of patients had 
tumours with positive estrogen and/or progesterone receptors (ER/PR+), 32% of patients had tumours with 
over-expression of Her-2-Neu receptor (HER2+), and 28% of patients had tumours with triple negative receptors. 
The majority of patients received a combined anthracycline and taxane-based chemotherapy (91%). Patients with 
ER+ tumours received hormonal therapy (tamoxifen) or an aromatase inhibitor (letrozole) in an adjuvant setting. 
No treatment regimen was modified based on the imaging findings in this observational study. Based on histopa-
thology of surgical specimens at post-treatment, 19 patients had a Miller-Payne score of 1 or 2 and were classified 
as pathological non-responders (progressive or stable disease with less than 30% reduction in tumour cellularity), 
whereas 81 patients had a score of 3–5 and were categorized as pathological responders (complete pathological 
response or partial response with more than 30% reduction in tumour cellularity). No significant differences were 
observed in tumor size changes assessed through physical examination at weeks one, four, and eight of treatment 
between the responding and non-responding patients.
Figures 1 and 2 demonstrate representative ultrasound B-mode images with QUS parametric overlays of MBF, 
slope, intercept, SAS, AAC and ASD, obtained prior to and at weeks 1, 4 and 8 after the start of chemotherapy 
from responding and non-responding patients, respectively. An overall increase in tumour echogenicity was 
detectable in responding patients after chemotherapy, as observed in parametric maps of MBF, intercept and 
AAC. No such increase was observed in the case of non-responding patients. Considerable changes were also 
observed in the textural characteristics of the QUS parametric maps acquired from the responding patient during 
the course of treatment, compared to pre-treatment (discussed further below).
Low- and high-magnification microscopy images acquired from whole-mount histopathology sections of 
surgical specimens for representative responding and non-responding patients are presented in Fig. 3. In the 
Mean ± Standard Deviation/
Percentage
Age 49 ± 11 years
Initial Tumour Size 5.9 ± 2.8 cm
Histology
Invasive Ductal Carcinoma: 95%
Invasive Lobular Carcinoma: 5%
Tumour Grade
Grade I: 10%
Grade II: 63%
Grade III: 27%
Molecular Features
ER/PR+: 63%
ER/PR+ & HER2−: 40%
HER2+: 32%
ER− & PR− & HER2+: 9%
ER− & PR− & HER2−: 28%
Residual Tumour Size 3.1 ± 4.0 cm
Miller-Payne Score
MP 1: 7%
MP 2: 12%
MP 3: 41%
MP 4: 15%
MP 5: 23%
Response
Responder: 81%
Non-responder: 19%
Table 1. Summary of patient characteristics and histopathological response to chemotherapy.
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histopathology images of responding patients, chemotherapy effect was clearly detectable with minimal tumour 
cellularity remaining within the tumour bed. In contrast, histopathology images of non-responding patients indi-
cated typically large areas of residual disease with minimal chemotherapy effects.
Average QUS data obtained from responding and non-responding patients over the course of treatment is pre-
sented in Figs 4 and 5. Figure 4 demonstrates the average changes from the baseline in QUS mean-value param-
eters for the two patient populations. Among the mean-value parameters, the MBF, intercept, SAS and AAC 
provided the best separations between the responding and non-responding patients that consistently increased 
over the course of treatment. The ACE parameter also provided a good separation between the two patient 
cohorts especially at weeks 1 and 8 of treatment. Table 2 summarizes the average changes in these parameters over 
the course of treatment for responding versus non-responding patients. Figure 5 demonstrates changes in a QUS 
textural parameter between the two patient groups. Specifically, the average changes in the homogeneity measure 
of the QUS parametric maps after the start of chemotherapy are presented. The QUS homogeneity parameters 
could better separate the two patient populations at week 1, and in some cases at week 4 of treatment, compared to 
their mean-value counterparts. Similarly, other QUS textural features including correlation, energy and contrast, 
in many cases, demonstrated a better ability to separate the responding and non-responding patients compared to 
the corresponding mean-value parameters at earlier time-points after the start of chemotherapy (weeks 1 and 4). 
Changes in other textural features of the QUS parametric maps over the course of treatment have been provided 
in Supplementary Figures 1–3.
Figure 1. Representative ultrasound B-mode images with QUS parametric overlays acquired from a 
responding patient prior to and at different times after the start of chemotherapy. The parametric maps 
demonstrate spatial variations in quantitative parameters (MBF, slope, intercept, SAS, ASD, and AAC) that are 
linked to tumour micro-structure. Changes in mean-value and textural features of these maps were monitored 
over the course of treatment to evaluate patient response to chemotherapy. The color bar represents a scale 
encompassing 35 dBr for MBF, 10 dBr/MHz for slope, 65 dBr for intercept, 3 mm for SAS, 150 µm for ASD, and 
55 dB/cm3 for AAC. The scale bar represents 5 mm.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 10352  | DOI:10.1038/s41598-017-09678-0
Table 3 presents the result of cross-validated response classification at different times after the start of chemo-
therapy using optimal subsets of QUS parameters identified through the feature selection process. At week 1 
of the treatment a combination of three textural parameters (slope-homogeneity, ASD-homogeneity, and 
SAS-energy) resulted in an accuracy of 82 ± 0.7% and an area under the ROC curve of 0.75 ± 0.1. A feature set of 
four textural parameters (slope-contrast, AAC-energy, SAS-correlation, ASD-correlation) classified the respond-
ing and non-responding patients at week 4 of the treatment with an accuracy of 86 ± 0.7% and an area under the 
ROC curve of 0.80 ± 0.1. At week 8 after the start of chemotherapy, one textural and three mean-value parameters 
(AAC, MBF, MBF-correlation, ACE) in combination could differentiate between the two patient populations with 
an accuracy of 85 ± 0.9% and an area under the ROC curve of 0.89 ± 0.1.
Figure 6 demonstrates results of recurrence-free survival analyses. The plots present the 5-year survival curves 
calculated for the responding and non-responding patients classified at weeks 1, 4 and 8 of treatment using the 
optimal QUS feature sets, compared to those at post-treatment based on the clinical-pathological outcome. A 
statistically significant difference was observed between the survival curves obtained based on the optimal QUS 
feature sets at week 1 (p = 0.002), week 4 (p = 0.0058) and week 8 (p = 0.0110) of treatment. Also, a statistically 
significant difference was indentified between the survival curves obtained months later based on the pathologi-
cal response of the patients (p < 0.0001).
Discussion and Conclusions
The results presented in this study from a cohort of 100 patients demonstrated a high accuracy of QUS bio-
markers for detecting responses of breast cancer patients to chemotherapy early after the start of treatment. 
One-hundred women with LABC were monitored during the course of their neoadjuvant chemotherapy and 
Figure 2. Representative ultrasound B-mode images with QUS parametric overlays (described in Fig. 1) 
acquired from a non-responding patient prior to and at different times after the start of chemotherapy. The color 
bar represents a scale encompassing 35 dBr for MBF, 10 dBr/MHz for slope, 65 dBr for intercept, 3 mm for SAS, 
150 µm for ASD, and 55 dB/cm3 for AAC. The scale bar represents 5 mm.
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evaluated in terms of standard clinical methods with respect to treatment outcome. The patients were monitored 
using QUS mean-value and textural parameters as non-invasive surrogates of therapy response over the course 
of treatment. The pathology-based responses of patients were assessed after surgery using whole-mount sections 
of surgical specimens. The results demonstrated that pathological responders and non-responders exhibited con-
siderably different trends of change in many QUS biomarkers over the course of treatment. Further, the QUS 
textural parameters often provided a better separation between the two patient populations early after the start of 
chemotherapy (weeks 1 and 4), compared to QUS mean-value parameters.
Previous in vitro and in vivo studies have demonstrated that nuclear condensation and fragmentation in cell 
death can modify ultrasonic backscatter properties of tissue, at high (above 15 MHz) and at clinically-relevant 
conventional low (3–9 MHz) frequencies44, 47, 48, 65. This is consistent with observations in this study, in which 
ultrasound backscatter characteristics were quantified by QUS parameters. Banihashmei et al. demonstrated that 
the cellular-based sub-resolution scatterers which alter with cell death can affect ultrasound backscatter signals at 
low-frequency and summarized the evidence for the role of cell death related nuclear changes43.
In the study here, a systematic feature selection process using balanced subsets of data was applied to form 
optimal QUS feature sets for response classification. These feature sets included three textural parameters for 
week 1, four textural parameters for week 4 and one textural and three mean-value parameters for week 8 of 
treatment. Using these small, yet efficient, feature sets, the patient responses were classified with cross-validated 
accuracies of 82%, 86% and 85% at weeks 1, 4 and 8, respectively. These results imply that the QUS biomarkers 
investigated in this study have a good potential to be applied for the early prediction of treatment response in 
patients undergoing cancer-targeting therapies.
The results obtained in this study indicate that changes in the textural characteristics of QUS parametric maps 
become apparent at early stages after the start of treatment, and will subsequently result in dominant changes in 
the mean values of these maps. This is in agreement with the observations of our previous study on a small cohort 
of patients54. Early changes in textural properties of QUS images in responding patients may be due to the fact 
that tumour response to anti-cancer therapies is a gradual process which affects tissue micro-structures hetero-
geneously. The heterogeneous nature of tumour cell death and response development can influence the textural 
properties of response-related QUS parametric images, especially at early stages. Previous pre-clinical studies 
on animal tumour models support the clinical results observed here. In those studies, ultrasound-based textural 
parameters were found to be more sensitive to cell death, compared to mean values of the spectral parameters53. 
Textural parameters were also capable of detecting changes in tissue micro-structures with a higher correlation to 
histological cell death, especially at early stages after chemotherapy exposure. A gradual late accumulation of het-
erogeneous alterations in tissue micro-structures is anticipated to result in more detectable changes in the mean 
values of the QUS parametric images at later stages51. In this study, better separations between the two patient 
populations were provided by the QUS mean-value parameters at week 8 of treatment, with more mean-value 
parameters selected within the optimal feature set for response classification.
Figure 3. Whole mount histopathology images from representative responding and non-responding patients, 
at low (top) and high (bottom) magnifications. The responding tumour has been completely degenerated 
by treatment. A large dense tumour with high cellularity is still present in histopathology images of the 
non-responding patient. The scale bars represent 5 mm and 500 µm in low and high-magnification images, 
respectively.
www.nature.com/scientificreports/
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Ultrasound biomarkers acquired as early as one week after the start of treatment indicated links to patient 
outcomes in terms of progression-free survival. At weeks 1, 4 and 8, combinations of a few ultrasound-based 
biomarkers could differentiate between patient outcomes with good agreement with those based on pathology, 
obtained months later after surgery. Such an early insight into patient outcomes could facilitate the decision of 
switching to a more effective therapy for treatment-refractory patients or even shifting to a salvage therapy, before 
it is potentially too late.
In the study here, the breast cancer molecular subtypes were not stratified in response classification based 
on the QUS biomarkers acquired during the course of chemotherapy. Different molecular subtypes of breast 
cancer potentially demonstrate various kinetics of response to chemotherapy. Therefore, it would be interesting 
to investigate the potential impact of molecular subtypes of breast cancer on therapy response evaluation using 
QUS biomarkers obtained at different times after the start of treatment. A larger cohort of patients with enough 
number of cases for each subtype is required for such study to permit a valid cross-validated evaluation.
Applications of other functional imaging modalities including MRI, PET, diffuse optical imaging (DOI), and 
elastography, have been investigated in a number of previous studies for cancer treatment response monitor-
ing9, 21–24, 66. Fluorine-18 fluorodeoxyglucose PET (18F-FDG-PET) has been reported to identify response-related 
changes in tumour as early as 8 days after the start of chemotherapy67. In another study, multi-parametric imaging 
using dynamic contrast enhanced MRI (DCE-MRI) in conjunction with diffusion-weighted MRI (DW-MRI) has 
been demonstrated a capacity to be used in classifying patient response (n = 33) after one cycle of neoadjuvant 
chemotherapy with an area under the curve of 0.8768. Unlike the most methods based on MRI and PET modali-
ties, the ultrasound-based biomarkers investigated in this study rely on intrinsic contrast alterations arising from 
changes in the acoustical characteristics of cancer cells when they die, and hence the method does not require 
Figure 4. Average data obtained from treatment responding (R) and non-responding (NR) patients, 
demonstrating changes in QUS mean-value parameters during the course of treatment. Error bars 
represent ± one standard error of the mean.
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injection of any exogenous contrast agents. In addition, ultrasound is a relatively inexpensive, portable and rapid 
imaging modality that can easily be used to monitor patient response at multiple times during a course of treat-
ment. The QUS techniques proposed here can potentially be implemented as software add-ons on any existing 
RF-enabled ultrasound system.
The potential of textural analysis techniques to extract relevant features of medical images has recently been 
reported in other clinical studies of tissue characterization41, 69. In particular, the observations of this study on 
the sensitivity of changes in tissue heterogeneities for an early assessment of treatment response is supported by 
other studies investigating textural biomarkers of cancer therapy response using MRI66, 70, 71, PET72, and CT73, 74. 
These studies confirm in principle that early changes in tissue micro-structure and function could be quantified 
using textural analysis techniques and, consequently, correlated to patient responses to anti-cancer therapies. A 
similar study has recently investigated the efficacy of textural parameters extracted from diffuse optical spectro-
scopic (DOS) images to evaluate treatment response in breast cancer patients24. Whereas the DOS mean-value 
Figure 5. Average data obtained from responding (R) and non-responding (NR) patients, demonstrating 
changes in homogeneity measure of the QUS parametric maps during the course of treatment. Error bars 
represent ± one standard error of the mean.
Feature
Week 1 Week 4 Week 8
R NR R NR R NR
MBF∆ (dBr) 2.4 ± 0.9 0.8 ± 1.7 3.4 ± 1.0 −0.7 ± 1.8 7.5 ± 0.9 −2.5 ± 1.4
Intercept∆ (dBr) 1.3 ± 0.9 −0.4 ± 1.6 3.0 ± 1.0 −0.7 ± 1.8 5.8 ± 1.2 −2.8 ± 1.5
SAS∆ (µm) −2.3 ± 13.9 −31.8 ± 16.7 10.0 ± 12.7 −18.3 ± 19.2 23.5 ± 17.0 −17.6 ± 14.1
AAC∆ (dB/cm3) 5.1 ± 1.9 4.5 ± 4.3 6.0 ± 2.7 1.4 ± 3.8 11.9 ± 1.6 −2.7 ± 1.9
ACE∆ (dB/cm.MHz) 0.2 ± 0.1 −0.1 ± 0.1 0.2 ± 0.1 0.1 ± 0.1 0.3 ± 0.1 0.14 ± 0.1
Table 2. The average changes (± one standard error of the mean) in the MBF, Intercept, SAS, AAC and ACE 
parameters at weeks 1, 4 and 8 of treatment for responding (R) versus non-responding (NR) patients.
Week Optimal Feature Set Sen (%) Spc (%) Acc (%) AUC
1 Slope-Homogeneity∆, ASD-Homogeneity∆, SAS-Energy∆ 83 ± 1.0 81 ± 1.1 82 ± 0.7 0.75 ± 0.1
4 Slope-Contrast∆, AAC-Energy∆, SAS-Correlation∆, ASD-Correlation∆ 90 ± 0.7 83 ± 1.4 86 ± 0.7 0.80 ± 0.1
8 AAC∆, MBF∆, MBF-Correlation∆, ACE∆ 97 ± 0.7 72 ± 1.6 85 ± 0.9 0.89 ± 0.1
Table 3. Results of cross-validated classification of chemotherapy response at weeks 1–4 after treatment using 
the optimal QUS features. Reported are average sensitivity (Sen), specificity (Spc), accuracy (Acc) and area 
under the curve (AUC) ± one standard error of the mean.
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parameters have previously indicated the potential to detect response to anti-cancer therapies22, textural char-
acteristics of DOS images, taking into account the heterogeneities in tumour physiology and metabolism, have 
been demonstrated to be more sensitive and specific for the classification of response to treatment. The spatial 
resolution in DOS imaging (~3 mm) is lower compared to the QUS imaging applied in this study (~200 µm), as 
the former probes the macroscopic metabolic activities at tissue and vascular levels whereas the latter visualizes 
microscopic functional activities of cell clusters. Nonetheless, DOS textural biomarkers have also been demon-
strated capable of detecting treatment-refractory patients early on during a course of chemotherapy. This further 
highlights the potential of image-based textural features at different resolutions to quantify changes in tissue 
micro-structure and functional activities in response to treatment. This potential for QUS parameters to serve as 
surrogates of response can be applied through a multi-modal multi-resolution imaging framework incorporating 
various complementary measures of response monitoring, and facilitating a more robust prediction of therapy 
response as early as possible after treatment initiation.
In conclusion, this study confirms that QUS parametric imaging in conjunction with textural analysis tech-
niques can be clinically applied to predict the pathological response of breast cancer patients to chemotherapy 
early after the start of treatment. Results indicate that treatment-refractory patients demonstrated different trends 
in measured ultrasound-based biomarkers over the course of treatment, compared to responding patients. The 
proposed biomarkers were also found to have a good cross-validated sensitivity and specificity to distinguish 
patients with poor pathological response to therapy as early as one week following the treatment. The promising 
results presented in this study imply that these QUS biomarkers, as early survival-linked surrogates of response 
to cancer-targeting therapies, could be applied to facilitate switching an inefficient treatment regimen to a more 
effective one on an individual patient basis, within few weeks after the therapy initiation75.
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